StreetInsider.com News Articles

OKYO Pharma CSO buys 3,363 shares at $1.49 each on Nasdaq

Tue, 28 Jul 2026 07:00:39 -0400

OKYO Pharma Limited (NASDAQ: OKYO) announced that its Chief Scientific Officer, Raj Patil, PhD, purchased 3,363 ordinary shares on the Nasdaq at $1.49 per share, according to a company statement.

The transaction brings Patil's total holding in the clinical-stage biopharmaceutical company to 20,030 ordinary shares.

OKYO Pharma CSO buys 3,363 shares at $1.49 each on Nasdaq

Tue, 28 Jul 2026 07:00:39 -0400

OKYO Pharma Limited (NASDAQ: OKYO) announced that its Chief Scientific Officer, Raj Patil, PhD, purchased 3,363 ordinary shares on the Nasdaq at $1.49 per share, according to a company statement.

The transaction brings Patil's total holding in the clinical-stage biopharmaceutical company to 20,030 ordinary shares.

Form 6-K OKYO Pharma Ltd For: Jul 28

Tue, 28 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260728/26822124.html

Form 6-K OKYO Pharma Ltd For: Jul 28

Tue, 28 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260728/26822124.html

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

Tue, 28 Jul 2026 07:00:00 -0400

LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company’s ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary shares.

About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

Tue, 28 Jul 2026 07:00:00 -0400

About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

Mon, 27 Jul 2026 07:00:00 -0400

LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026.

Company Participation: Robert J. Dempsey, Chief Executive Officer, Keeren Shah, Chief Financial Officer, Flavio Mantelli MD, PhD, Chief Medical Officer

Date/Time: July 28-29, 2026

Location: Virtual

1:1 Meetings: schedule a one-on-one meeting with management by contacting your BTIG representative

Form 6-K OKYO Pharma Ltd For: Jul 27

Mon, 27 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260727/26815784.html

Form 6-K OKYO Pharma Ltd For: Jul 27

Mon, 27 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260727/26815784.html

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

Mon, 27 Jul 2026 07:00:00 -0400

Company Participation: Robert J. Dempsey, Chief Executive Officer, Keeren Shah, Chief Financial Officer, Flavio Mantelli MD, PhD, Chief Medical Officer

Date/Time: July 28-29, 2026

Location: Virtual

1:1 Meetings: schedule a one-on-one meeting with management by contacting your BTIG representative

Form 4 OKYO Pharma Ltd For: Jul 22 Filed by: Dempsey Robert John

Thu, 23 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260723/26808385.html

Form 4 OKYO Pharma Ltd For: Jul 22 Filed by: Dempsey Robert John

Thu, 23 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260723/26808385.html

Form 4 OKYO Pharma Ltd For: Jul 22 Filed by: Dempsey Robert John

Thu, 23 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260723/26808385.html

Form 4 OKYO Pharma Ltd For: Jul 21 Filed by: CERRONE GABRIELE M